Walter M Gregory
Overview
Explore the profile of Walter M Gregory including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
3350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Howard D, Munir T, McParland L, Rawstron A, Chalmers A, Gregory W, et al.
Health Technol Assess
. 2017 Jun;
21(28):1-374.
PMID: 28628003
Background: The conventional frontline therapy for fit patients with chronic lymphocytic leukaemia (CLL) is fludarabine, cyclophosphamide and rituximab (FCR). Rituximab (Mabthera, Roche Products Ltd) targets the CD20 antigen, which is...
22.
Heaney J, Campbell J, Griffin A, Birtwistle J, Shemar M, Child J, et al.
Br J Haematol
. 2017 Jun;
178(2):220-230.
PMID: 28573706
This study aims to guide the integration of serum free light chain (sFLC) tests into clinical practice, including a new rapid test (Seralite ). Blood and urine analysis from 5573...
23.
Howard D, Brown J, Todd S, Gregory W
Stat Methods Med Res
. 2016 Sep;
27(5):1513-1530.
PMID: 27647808
Multi-arm clinical trials assessing multiple experimental treatments against a shared control group can offer efficiency advantages over independent trials through assessing an increased number of hypotheses. Published opinion is divided...
24.
Munshi N, Avet-Loiseau H, Rawstron A, Owen R, Child J, Thakurta A, et al.
JAMA Oncol
. 2016 Sep;
3(1):28-35.
PMID: 27632282
Importance: Numerous studies have evaluated the prognostic value of minimal residual disease (MRD) in patients with multiple myeloma (MM). Most studies were small and varied in terms of patient population,...
25.
Pawlyn C, Kaiser M, Heuck C, Melchor L, Wardell C, Murison A, et al.
Clin Cancer Res
. 2016 May;
22(23):5783-5794.
PMID: 27235425
Purpose: Epigenetic dysregulation is known to be an important contributor to myeloma pathogenesis but, unlike other B-cell malignancies, the full spectrum of somatic mutations in epigenetic modifiers has not been...
26.
Gregory W, Twelves C, Bell R, Smye S, Howard D, Coleman R, et al.
Breast Cancer Res Treat
. 2016 Jan;
155(2):303-11.
PMID: 26783036
We designed a mathematical model to describe and quantify the mechanisms and dynamics of tumor growth, cell-kill and resistance as they affect durations of benefit after cancer treatment. Our aim...
27.
De Tute R, Rawstron A, Gregory W, Child J, Davies F, Bell S, et al.
Haematologica
. 2015 Oct;
101(2):e69-71.
PMID: 26471484
No abstract available.
28.
Kuiper R, van Duin M, van Vliet M, Broijl A, van der Holt B, El Jarari L, et al.
Blood
. 2015 Sep;
126(17):1996-2004.
PMID: 26330243
Patients with multiple myeloma have variable survival and require reliable prognostic and predictive scoring systems. Currently, clinical and biological risk markers are used independently. Here, International Staging System (ISS), fluorescence...
29.
Walker B, Boyle E, Wardell C, Murison A, Begum D, Dahir N, et al.
J Clin Oncol
. 2015 Aug;
33(33):3911-20.
PMID: 26282654
Purpose: At the molecular level, myeloma is characterized by copy number abnormalities and recurrent translocations into the immunoglobulin heavy chain locus. Novel methods, such as massively parallel sequencing, have begun...
30.
Walker B, Wardell C, Murison A, Boyle E, Begum D, Dahir N, et al.
Nat Commun
. 2015 Apr;
6:6997.
PMID: 25904160
We have sequenced 463 presenting cases of myeloma entered into the UK Myeloma XI study using whole exome sequencing. Here we identify mutations induced as a consequence of misdirected AID...